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Abstract
It has been demonstrated that secretion of several hormones can be classically conditioned,
however, the underlying brain responses of such conditioning have never been investigated
before. In this study we aimed to investigate how oxytocin administration and classically
conditioned oxytocin influence brain responses. In total, 88 females were allocated to one of
three groups: oxytocin administration, conditioned oxytocin, or placebo, and underwent an
experiment consisting of three acquisition and three evocation days. Participants in the con-
ditioned group received 24 IU of oxytocin together with a conditioned stimulus (CS) during
three acquisition days and placebo with the CS on three evocation days. The oxytocin
administration group received 24 IU of oxytocin and the placebo group received placebo
during all days. On the last evocation day, fMRI scanning was performed for all participants
during three tasks previously shown to be affected by oxytocin: presentation of emotional
faces, crying baby sounds and heat pain. Region of interest analysis revealed that there
was significantly lower activation in the right amygdala and in two clusters in the left superior
temporal gyrus in the oxytocin administration group compared to the placebo group in
response to observing fearful faces. The activation in the conditioned oxytocin group was in
between the other two groups for these clusters but did not significantly differ from either
group. No group differences were found in the other tasks. Preliminary evidence was found
for brain activation of a conditioned oxytocin response; however, despite this trend in the
expected direction, the conditioned group did not significantly differ from other groups.
Future research should, therefore, investigate the optimal timing of conditioned endocrine
responses and study whether the findings generalize to other hormones as well.
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Introduction
It has been shown that after repeated administration of medication that triggers a physiological
change (unconditioned response), with an initially neutral conditioned stimulus (CS; such as,
a taste or smell of the medication or the medication administration procedure), the CS alone
can cause this physiological change [1]. This principle is known as pharmacological condition-
ing. It has been proposed that physiological responses to a CS help organisms to adapt their
state in preparation for an upcoming change and in this way maintain homeostasis [2]. The
principle of pharmacological conditioning has been demonstrated for various hormonal and
immune parameters. For example, some evidence indicates that cortisol levels can be
decreased by presenting participants with a distinctive drink previously coupled with a suma-
triptan injection [3] and increased by giving a placebo injection that was previously coupled
with dexamethasone [4]. Evidence of the effects of pharmacological conditioning also exists
for other hormones, such as growth hormone [4] and insulin [5], and for immune parameters,
such as interleukin-2 [6], natural cell killer activity [7] and histamine [8].
Despite extensive research in the field of pharmacological conditioning, no studies so far
investigated neural mechanisms underlying this phenomenon. From the pain conditioning lit-
erature, it is known that conditioned analgesia decreases brain activation in pain-sensitive
brain regions, such as the thalamus, insula, and dorsal anterior cingulate cortex [9]. It can be
hypothesized that, similarly to the pain conditioning findings, pharmacological conditioned
responses might trigger similar brain areas that are activated by the unconditioned stimulus
(i.e., the medication).
In the present study, we examined for the first time the neural underpinnings of pharmaco-
logical conditioning with oxytocin. Oxytocin is a peptide hormone produced in the hypothala-
mus and is found to have a wide range of effects on brain activity. Its receptors are densely
situated in the hypothalamus, amygdala, olfactory bulbs, and cingulate cortex [10], areas that
are also associated with maternal care, social attachment and emotional processing [11]. It has
been repeatedly demonstrated that exogenously administered oxytocin modifies brain
responses to emotional [12, 13] and aversive visual stimuli [14], motivational tasks, involving
trust [15], empathy [16], reward [17], and pain [18–20]. Particularly, oxytocin has been shown
to reduce amygdala activation in response to aversive [14] and painful stimuli [20], which can
be an underlying mechanism of stress reducing [21] and analgesic [22] effects of oxytocin
described in previous research. Considering these positive physiological and psychological
effects of oxytocin, pharmacological conditioning of oxytocin might have important clinical
implications both in somatic and mental health. In this randomized placebo-controlled trial,
we investigated the effects of oxytocin administration and conditioned oxytocin in comparison
to a placebo-control group on brain activation in response to fMRI tasks that have previously
shown to be affected by exogenous oxytocin administration: presentation of emotional faces
[12], presentation of crying baby sounds [23] and thermal pain stimulation [18, 20]. We
expected that the conditioned oxytocin group would demonstrate comparable brain activation
patterns as the group that received exogenous oxytocin. Particularly, in response to the presen-
tation of emotional faces, we expected that exogenous and conditioned oxytocin would reduce
the activation in bilateral amygdala, and increase the activation in the insula, the occipital fusi-
form gyrus, and the superior temporal gyrus. We also expected that exogenous and condi-
tioned oxytocin would decrease activation in the bilateral amygdala and increase activation in
the insula and the inferior frontal gyrus pars triangularis in response to the sounds of crying
babies. Finally, we expected that exogenous and conditioned oxytocin would decrease activa-
tion in the bilateral amygdala in response to pain stimulation. We also hypothesized that the
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changes in brain activation triggered by conditioned oxytocin, would be smaller in magnitude
than the changes cause by exogenous oxytocin administration.
Materials and methods
Participants
This study is part of a study on the effects of pharmacological conditioning of oxytocin effects
in which in total 99 healthy female volunteers were included [24]. Of this initial sample, 88 par-
ticipants took part in the MRI part of this study (11 participants did not continue with the last
part due to health and planning reasons). Participants were randomly (based on a 1:1:1 ratio
with a block randomization and a block size of 8) assigned to three groups: an oxytocin admin-
istration group (29 participants), a conditioned oxytocin group (29 participants), and a placebo
control group (30 participants). Participants were screened for the following exclusion criteria:
intake of analgesic and anti-inflammatory medication at the moment of the experiment, psy-
chiatric, somatic, severe neurological or neurosurgical conditions that could interfere with the
participant’s safety or the study protocol, left-handedness, non-removable metal parts in the
body, claustrophobia, (intended) pregnancy or breast feeding, and heavy use of alcohol or
drugs. Only female participants were included into the study as the effects of oxytocin on brain
activation have been shown to differ between the sexes [25, 26], and although this choice limits
generalizability of the findings it enhances statistical power. Moreover, only participants who
used oral contraceptives were included in the trial to have a better control of menstrual cycle
related hormonal changes [27]. Participants were scanned in the weeks when they used oral
contraceptives, not in their stop week. Participants were asked to refrain from drinking alcohol
and doing intense physical exercise 24 hours before the sessions and drinking caffeinated
drinks two hours before the sessions.
The study was approved by the Medical Ethical Committee of Leiden University Medical
Centre (NL52683.058.15). All participants gave written informed consent to participate in the
experiment and were debriefed and financially compensated afterwards.
Sample size
The sample size was calculated with software G�Power 3. The calculation was done on the
basis of a pilot experiment on conditioning of cortisol responses performed in our lab, as the
design of this pilot corresponded to the design of the present study. The effect size found in the
pilot experiment was d = 0.527. It was shown that 33 participants per group were necessary to
obtain a power of .95 at an alpha level of a = .05. The power analysis was aimed at the question
of the possibility to condition oxytocin release and not on the fMRI part of the trial.
The number of participants excluded at each step of the experiment is presented on Fig 1.
One participant was not able to perform the faces task due to a technical problem with the
computer. The data of one participant from the conditioned group was excluded from the
analysis due to excessive head motion (frame displacement > 1 mm on 50 slices) leaving data
of 86 participants that were included in the analysis of the faces task (29 participants in the
oxytocin administration group, 28 participants in the oxytocin conditioned group, 29 partici-
pants in the placebo group).
Due to a technical problem with the audio system, 5 participants were not able to perform
the crying baby sounds task. Additionally, data of 5 participants were excluded due to excessive
head motion (frame displacement > 1 mm on 75–322 slices). Data of 78 participants in total
were therefore included into the analysis of the crying baby sounds task (26 oxytocin adminis-
tration group, 23 conditioned oxytocin group, 29 placebo group).
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Fig 1. CONSORT flow diagram.
https://doi.org/10.1371/journal.pone.0229692.g001
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Due to technical problems with the thermode, 74 of 88 participants could take part in the
pain task. Data of all of them were included in the analysis of the pain task (24 oxytocin admin-
istration group, 25 conditioned oxytocin, 25 placebo group).
Study design
The study had a single-blind design. Participants were randomly allocated to one of the three
groups and did not know whether they received the oxytocin or the placebo spray. Researchers
knew which participants were included in the oxytocin administration group (due to the
absence of the CS in the evocation phase). However, researchers stayed blinded regarding the
conditioned oxytocin and placebo groups. The randomization was performed by the Clinical
Pharmacy of Leiden University Medical Centre using block randomization. The researchers
received the randomization list after the study was completed. The trial was preregistered as a
clinical trial on www.trialregister.nl (number NTR5596).
Procedures
The detailed procedures of the trial have been described elsewhere [24]. Briefly, after an initial
screening, participants were randomly allocated to an oxytocin administration group, a condi-
tioned oxytocin group, or a placebo control group. In line with previous conditioning studies
[28, 29], a two-phase conditioning paradigm with an acquisition phase and an evocation phase
was used. Both phases lasted for three consecutive days with a four-day break in between to
allow wash-out of potential residual oxytocin effects from the previous phase. In the condi-
tioned oxytocin group, the procedure was the following: in the acquisition phase, an associa-
tion between a US (24 IU of oxytocin nasal spray) and a CS (a smell of rosewood oil) was
established. Participants were administered the oxytocin spray which was immediately pre-
ceded and immediately followed by an odor of rosewood oil that was presented via a custom-
made olfactometer (Wiff Online). In the evocation session, participants were administered a
placebo spray paired with the same odor as in the acquisition phase. Participants in the placebo
group underwent the same procedures but instead of the oxytocin spray they received a pla-
cebo spray during both phases. Participants in the oxytocin administration group received the
oxytocin spray during both acquisition and evocation phases, however, they did not receive a
CS during the evocation phase in order to avoid the occurrence of a conditioned response.
The MRI experiment described in this study was performed on the third (last) evocation day
in order to keep the conditioning context stable through the first experimental sessions.
On this third evocation day, upon arrival to the lab, participants were asked to provide a
baseline saliva sample to measure their baseline oxytocin levels. Afterwards, placebo nasal
spray with the odor of rosewood oil or oxytocin spray without the odor was administered,
depending on group allocation. Five minutes after the spray administration, participants gave
a second saliva sample and went to another lab (5-minute walk) to participate in the MRI part
of the experiment.
The MRI scanning started approximately 50 minutes after the spray administration. First,
an anatomical scan was performed. This was followed by several functional scans in a fixed
order: the emotional faces task, the crying sounds task and finally the pain task. In total, scan-
ning lasted for around 50 minutes.
The data were collected in the laboratory facilities of Leiden University and Leiden Univer-
sity Medical Centre. The data were collected between February, 2016 and August, 2017.
Oxytocin analysis. Oxytocin levels were measured in saliva. Each sample contained a
minimum of 1.5 ml saliva that was collected with a passive drool method. Commercial ELISA
kits with extraction (Enzo Life Sciences, Farmingdale, NY) were used for assaying salivary
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oxytocin. Lower level of detection for oxytocin was 0.5 pg/ml after extraction. Extraction effi-
ciency was 99%. Intra-assay coefficient of variation was 10.2%. Inter-assay coefficient of varia-
tion was 11.8%.
Faces task. Color photographs of males and females with four different emotional facial
expressions (neutral, fearful, happy, and angry) from the Radboud Faces Database [30] were
used. The pictures were grouped in blocks of 5 male and 5 female pictures of each particular
valence. Each picture was presented for 1300 milliseconds with an interstimulus interval of
100 milliseconds and a block duration of 13.9 seconds. A total number of 16 blocks (4 blocks
of each valence) were presented in randomized order with inter-block intervals of 10 seconds
(total time of the stimulation: 7.56 minutes or 454 seconds). Stimulus presentation and
response registration were controlled using E-Prime 2.0 software (Psychology Software Tools,
Pittsburgh, PA).
During this task, participants were asked to focus on the screen and observe blocks of pho-
tos with faces. They were subsequently asked to rate the emotional arousal of each block on a
scale from 1 (not arousing at all) to 4 (very arousing). The rating was done during the between
block pause of 10 seconds. Participants could provide their ratings using button boxes placed
on their thighs that were within easy reach.
Crying baby sounds task. The crying baby sounds task used in the current study was sim-
ilar to the one that has been extensively described in previous studies [23, 31]. The crying
sounds were recorded from a 2-day old child. The control sounds were digitally created identi-
cal to the crying sounds in terms of duration, intensity, spectral content, and amplitude enve-
lope but lacking an emotional meaning [31]. The sounds were presented in 48 blocks (24
crying sounds and 24 control sounds) of 10 seconds with 6 seconds in between in randomized
order. The order of the blocks was randomized within each participant. Participants were
asked to focus on the sounds during the task.
Pain task. Pain stimuli were delivered with a standardized heat pain application device
(fMRI-compatible ATS thermode attached to a Pathway device, Medoc Advanced Medical
Systems, Ramat Yishai, Israel). The ATS thermode was applied to the dorsal site of the left arm
of the participants when they were lying in the scanner. Before performing the functional scan,
but within the scanner room, the temperature that elicited a medium pain intensity of 6 on a 0
to 10 numeric rating scale (0- no pain at all; 10- the worst pain imaginable) was identified for
each participant. For this purpose, participants received a sequence of ascending temperatures
with a peak temperature lasting for 5 seconds and an inter-stimulus interval of 15 seconds. Par-
ticipants were asked to rate each stimulus using a 0 (no pain) -10 (worst pain imaginable)
Numerical Rating Scale (NRS). The temperature that was rated as eliciting pain of 6 was used
subsequently during the following functional MRI.
The pain task immediately followed the individual calibration phase and consisted of alter-
nating 7 heat pain stimuli with a peak temperature lasting for 15 seconds, and 6 baseline sti-
muli of neutral to slightly warm (32 degrees Celsius) temperatures lasting between 13 and 17
seconds (on average 15 seconds) each. The purpose of the variable inter-stimulus times was to
avoid anticipatory pain responses. Participants were instructed to focus on the sensation they
experienced and were given the opportunity to stop the task at any moment by pressing an
alarm bell. No participants pressed the alarm bell during the experiment.
Image acquisition
The MRI data were acquired on a Philips 3T MR-system (Best, The Netherlands) in the Leiden
University Medical Centre. First, a T1 weighted high resolution anatomical scan was acquired
(repetition time (TR) = 9.8 milliseconds, echo time (TE) = 4.6 milliseconds, flip angle = 8˚;
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voxel size 0.875 x 0.875 x 1.2; 140 slices). Functional data were acquired with echoplanar
images (EPI) using a T2�-weighted gradient echo sequence (TR = 2200 milliseconds; TE = 30
milliseconds; flip angle = 80˚; voxel size 2.75 × 2.75 × 2.75 millimetres +10% slice gap, 38 trans-
verse slices). Images were scanned parallel to the anterior–posterior commissure plane.
Statistical analysis of demographic and psychological variables
Group differences in age, BMI, and baseline oxytocin salivary levels from the screening and
three evocation days were examined using one-way analysis of variance (ANOVA).
To investigate whether there was significant conditioned oxytocin release, the conditioned
oxytocin group was compared to the placebo group without adding the exogenous oxytocin
group into the analysis (as extremely high oxytocin levels were expected in the exogenous oxy-
tocin group which was decided prior to the study in the study registration protocol). The com-
parison was done with three (for each evocation day separately) repeated measures analyses of
covariance (ANCOVA) with baseline oxytocin levels as a covariate. Next, the oxytocin admin-
istration group was added to the analyses and the three groups were compared on salivary oxy-
tocin levels after the spray administration with repeated measures analyses of covariance in
which baseline oxytocin levels served as a covariate.
To investigate whether exogenous or conditioned oxytocin had an effect on the arousal rat-
ings given during the Faces task, arousal ratings of faces were compared between the groups
with a factorial 4 (face valence: neutral, happy, angry or fearful) x 3 (group: oxytocin adminis-
tration, placebo, conditioned oxytocin) ANOVA.
Finally, an ANOVA was used to compare the groups on the temperatures that elicited a
pain of 6 (on an 11-point NRS) that were used during the Pain task.
Image preprocessing and analyses
The data were pre-processed and analysed with FSL software Version 5.0.10 (FMRIB’s Soft-
ware Library, www.fmrib.ox.ac.uk/fsl [32]). Brain extraction from the anatomical scans was
done using the Brain Extraction Tool as implemented in FSL [33]. Motion correction of func-
tional scans was done using MCFLIRT [34]. Spatial smoothing was applied using a Gaussian
kernel of full-width-at-half-maximum = 5 mm. High-pass temporal filtering was applied to the
data (for faces task with high pass filter cut-off = 60 seconds; for crying baby sounds task fil-
ter = 50 seconds; for pain task filter = 90 seconds). Functional scans were registered to T1
weighted images, using Boundary-Based Registration, and then registered to an MNI-152 stan-
dard space image (Montreal Neurological Institute, Montreal, QC, Canada) using non-linear
registration with a warp resolution of 10 millimetres.
The analysis consisted of three levels. The first level analysis was performed using general
linear models. Blocks (for the faces task: angry, happy, fearful, neutral; for the crying baby
sounds task: crying sounds, control sounds; for the pain task: painful stimuli, control stimuli)
were used as predictors and convolved with a double-gamma hemodynamic response function
and its temporal derivatives. Regression coefficients were estimated in FSL. For the faces task,
six contrasts were estimated: angry >/< neutral, happy >/< neutral, fearful >/< neutral. For
the crying baby sounds task, two contrasts were estimated: cry >/< control. For the pain task,
two contrasts were estimated: pain >/< control. These first level contrasts were submitted to
the second level analysis that was separately run per group. Within the second level analysis,
the effects of the tasks on the brain activation were investigated in each group separately.
Finally, to investigate the differences between the three groups, the third level analysis was per-
formed. The three groups were compared with each other using analysis of variance on the
contrasts. The Randomise tool of FSL was used to perform voxel-wise permutation-based
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non-parametric testing and generate statistical inference for the analysis of variance. 5000 per-
mutations per contrast were done. The statistical tests were corrected for multiple comparisons
with the threshold-free cluster enhancement (TFCE). A TFCE corrected statistical threshold of
p< 0.05 was chosen.
For exploratory purposes, these analyses were first performed on the whole brain (as in
Domes and colleagues [35] and Riem and colleagues [31]). Second, a region of interest analysis
was run. The regions of interest were chosen based on previous literature. Based on a recent
meta-analysis on the effects of oxytocin on the brain activity in response to emotion processing
tasks [26], the following regions of interest were chosen for the faces task: the bilateral amyg-
dala, the bilateral insula, the bilateral occipital fusiform gyrus and bilateral superior temporal
gyrus. For the crying baby sounds task, the bilateral amygdala, bilateral insula and the bilateral
inferior frontal gyrus pars triangularis were chosen as regions of interest [31, 36]. For the pain
task, left and right amygdala separately were chosen as areas of interest [20]. The masks for the
regions of interest were taken from the Harvard-Oxford Cortical and Subcortical Structural
Atlases (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/data/atlas-descriptions.html).
Results
Baseline characteristics
There were no significant differences between the three groups on age (F (2, 87) = 0.495,
p = 0.611) and body mass index (F (2, 87) = 1.083, p = 0.343); the average age across the groups
was 21.5 years (SD = 2.4) and mean BMI was 22.38 (SD = 2.4).
Salivary oxytocin levels
The salivary levels of the whole sample (99 participants) during all experimental days are pre-
sented elsewhere [24]. Here we present the data of the sample of 88 participants who were
included in the MRI part of the experiment. Due to clogging of the saliva samples (i.e., the
saliva was thickened and could not be analyzed), 48 samples could not be analysed while 832
samples were included in the analysis. Mean salivary oxytocin levels across the groups and
measurement moments and the number of analysed samples per group are presented in
Table 1.There were no significant differences between the three groups on baseline salivary
oxytocin levels on the screening (F (2, 80) = 1.01, p = .369), evocation day 1 (F (2, 83) = 1.47,
p = 0.234), 2 (F (2, 84) = 0.37, p = 0.964) and 3 (F (2, 83) = 0.53, p = 0.588). There was a signifi-
cant difference between the conditioned oxytocin and placebo groups in the levels of oxytocin
Table 1. Mean salivary oxytocin levels (pg/ml) and standard deviations (SD) across the groups and measurement moments.
Test day Measurement Placebo group Oxytocin administration group Conditioned oxytocin group
Screening Baseline 12.57 (SD = 12.62, n = 30) 9.66 (SD = 6.66, n = 25) 15.32 (SD = 20.08, n = 26)
Evocation day 1 Baseline 16.94 (SD = 19.64, n = 30) 12.21 (SD = 7.05, n = 26) 11.68 (SD = 8.97, n = 28)
+ 5 minutes 14.85 (SD = 7.65, n = 30) 1912.79 (SD = 2429.66, n = 25) 28.34 (SD = 44.63, n = 28)
+ 20 minutes 13.77 (SD = 8.47, n = 30) 1020.81 (SD = 1860.49, n = 25) 20.17 (SD = 28.76, n = 28)
+ 50 minutes 10.18 (SD = 5.1, n = 30) 848.15 (SD = 1569.4, n = 26) 21.17 (SD = 25.99, n = 28)
Evocation day 2 Baseline 13.23 (SD = 8, n = 30) 13.01 (SD = 9.32, n = 27) 13.24 (SD = 7.12, n = 28)
+ 5 minutes 13.97 (SD = 6.6, n = 30) 1727.86 (SD = 2272.05, n = 25) 30.89 (SD = 70, n = 28)
+ 20 minutes 13.14 (SD = 5.62, n = 30) 1102.87 (SD = 1650.52, n = 25) 17.36 (SD = 15.37, n = 28)
+ 50 minutes 11.08 (SD = 5.66, n = 30) 826.88 (SD = 1666.11, n = 26) 10.14 (SD = 7.55, n = 28)
Evocation day 3 Baseline 16.85 (SD = 21.56, n = 30) 14.84 (SD = 13.6, n = 26) 12.14 (SD = 12.91, n = 28)
+ 5 minutes 12.19 (SD = 7.49, n = 30) 1719.83 (SD = 2639.64, n = 24) 20.24 (SD = 43.93, n = 27)
https://doi.org/10.1371/journal.pone.0229692.t001
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after the CS administration on the evocation day1: the conditioned oxytocin group had higher
salivary oxytocin levels in comparison to the placebo group after controlling for the baseline
levels (F (1, 55) = 5.98, p = 0.02). No differences between conditioned oxytocin and placebo
groups were found on the salivary oxytocin level on the evocation day 2 (F (1, 55) = 1.84,
p = 0.18) and evocation day 3 (F (1, 55) = 1, p = 0.32). When the oxytocin administration
group was added to the analysis, a significant main effect of group was found on evocation day
1 (F (2, 79) = 14.92, p< 0.001), evocation day 2 (F (2, 79) = 15.29, p< 0.001) and evocation
day 3 (F (2, 80) = 11.68, p< 0.001). Post hoc Bonferroni comparison demonstrated that the
oxytocin administration group had significantly higher salivary oxytocin levels than the pla-
cebo and the conditioned oxytocin group after controlling for the baseline levels during all
evocation days (all p’s< .001).
Faces task
First, to examine the effects of the emotional faces’ stimuli on brain activation, we looked at
the second level analysis, with a specific focus on the placebo group to see the effects of the task
on the brain activity regardless of the effects of oxytocin. The results of the second level analy-
sis are presented in Table 2 (for all three groups separately) and in the Supporting Information
(S1–S4 Figs). Full brain analysis in the placebo group (first column in Table 2) revealed a sig-
nificant activation in two clusters in the right and left occipital fusiform gyrus, one cluster in
the right superior temporal gyrus and one cluster in the right inferior temporal gyrus for the
contrast fearful > neutral faces. The ROI analysis additionally showed clusters in the right
amygdala, the right insula, the bilateral occipital fusiform gyrus and the bilateral superior tem-
poral gyrus that were significantly active on the contrast fearful > neutral faces. Additionally,
heightened activation in the left occipital fusiform gyrus was found on the contrast
happy > neutral faces in the ROI analysis.
In the third level brain analysis we compared the three groups with each other. The whole
brain analysis of variance with all three groups (oxytocin administration, conditioned oxytocin
and placebo) demonstrated no significant differences in any of the three contrasts. The ROI
analysis revealed that there was significantly higher activation in the right amygdala in the pla-
cebo group in comparison to the oxytocin administration group on the contrast
fearful> neutral. To explore this result in detail, we plotted z-values and standard deviations
of the three groups for this significant cluster (Fig 2). The z-values of the conditioned oxytocin
group were in between the values of the oxytocin administration and placebo groups but did
not significantly differ from either of these groups. Additionally, ROI analysis yielded a signifi-
cant difference between placebo and oxytocin administration group in the left superior tempo-
ral gyrus: the activation in the oxytocin administration group was significantly lower than in
the placebo group on the contrast fearful > neutral (Fig 3). The Z-values of the conditioned
oxytocin group were, again, in between the values of the oxytocin administration and placebo
groups but did not significantly differ from either of these groups. No significant activation
was found in other regions of interest.
No differences were found between the groups in the arousal ratings given during the task
(F (2, 77) = 0.15, p = .858). There was a significant difference in how arousing participants
found faces of different modality (F (3, 77) = 116.85, p< .001). Bonferroni corrections demon-
strated there were significant differences between all couples of modalities (all p’s < .05) and
that happy faces were found to be the most arousing (M = 3.00), followed by fearful faces
(M = 2.75), and angry faces (M = 2.50). Neutral faces (M = 1.23) were rated as the least
arousing.
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Crying baby sounds task
The results of the second level analysis of the Sounds task are presented in Table 3 and in the
Supporting Information (S5–S7 Figs). First, we again explored the effects of the sounds on the
brain activation in the placebo group alone (first column of Table 3). The whole brain analysis
showed higher activation in one large cluster in the right superior temporal gyrus with exten-
sion to the planum polare and one cluster in the left planum polare on the cry> control
sounds contrasts. Subsequent ROI analysis showed that the cry> control sounds contrast
caused significant activation in the right and left amygdala, the right and left insula and the left
inferior frontal gyrus pars triangularis. The third level analysis with the comparison between
the three groups revealed neither significant differences in the whole brain level nor in the
ROI analyses.
Table 2. Effects of face valence across the groups (second level analysis).
Placebo group (n = 29) Oxytocin administration group (n = 29) Conditioned oxytocin group (n = 28)
Cluster
size
T
max
X
(mm)
Y
(mm)
Z
(mm)
Cluster
size
T
max
X
(mm)
Y
(mm)
Z
(mm)
Cluster
size
T
max
X
(mm)
Y
(mm)
Z
(mm)
1. Neutral < angry
ROI left amygdala 2 6.17 -34 -8 -20
ROI left OFG 23 4.21 -22 -88 -10
1. Neutral > angry
ROI right insula 20 4.31 34 -14 -2
2. Neutral < happy
WB left occipital pole 5 4.71 0 -92 -6
WB left occipital pole superior
devision
50 5.61 -16 -98 4
WB right occipital pole 34 5.27 12 -102 6
16 6.41 16 -102 -2
ROI left OFG extending to
occipital pole
4 4.36 -18 -96 -4 746 4.91 -6 -92 -10
3.Neutral < fearful
WB bilateral OFG 4573 8.18 22 -90 -6
WB left OFG extending to
lateral occipital cortex
591 6.01 -28 -86 -12 16 4.79 -36 -84 -10
200 5.38 -22 -80 -10
WB right OFG extending to
lateral occipital cortex
232 5.15 28 -88 -10 376 6.25 22 -88 -10
WB right STG posterior
division
123 4.83 46 -36 4
WB right inferior temporal
gyrus, temporooccipital part
24 4.29 46 -52 -8
ROI right amygdala 16 3.39 28 6 -22
ROI right insula 22 3.5 36 26 0
ROI bilateral OFG 3679 6.01 -28 -86 -12 4535 8.18 22 -90 -6 869 5.38 -22 -88 -10
1088 6.25 22 -88 -10
ROI left OFG 60 4.76 -46 -12 -12
ROI right OFG 253 4.83 46 -36 4
WB- results obtained with the whole brain analysis; ROI- results obtained with the region of interest analysis; OFG- occipital fusiform gyrus; STG- superior temporal
gyrus. Reported activations are corrected for multiple comparisons with the threshold-free cluster enhancement. Coordinates are reported using the Montreal
Neurologic Institute space.
https://doi.org/10.1371/journal.pone.0229692.t002
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Fig 2. Cluster in right amygdala, contrast neutral< fearful. Cluster (28, 8, -24; t max = 3.81, cluster size = 4) with the significantly lower activation in the
oxytocin group in comparison to the placebo group on the contrast neutral< fearful and Z statistics with standard deviations from this cluster.
https://doi.org/10.1371/journal.pone.0229692.g002
Fig 3. Clusters in left superior temporal gyrus, contrast neutral< fearful. Clusters in the left superior temporal gyrus (cluster 1: -50, -32, 0; t max = 4.23,
cluster size = 41; cluster 2: -46, -10, -12; t max = 4.84; cluster size = 14) with the significantly lower activation in the oxytocin group in comparison to the
placebo group on the contrast neutral< fearful and mean Z statistics with standard deviations from these clusters.
https://doi.org/10.1371/journal.pone.0229692.g003
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Pain task
The results of the second level analysis of the Pain task are presented in Table 4 and in the Sup-
porting Information (S1–S4 Figs). The effects of pain stimulation on brain activity were again
first examined in the placebo group alone (first column of the Table 4). The whole brain analy-
sis revealed significant activation in 12 clusters across the brain on the contrast pain > control
and in 1 cluster on the contrast control> pain (for the details see Table 4). Significantly
increased activation in both the left and right amygdala were found on the ROI analysis on the
contrast pain > control. The third level analysis, comparing the three groups, revealed no sig-
nificant effect of oxytocin administration or conditioning with oxytocin on brain activity nei-
ther in the whole brain analysis nor in the ROI analysis with left and right amygdala.
Finally, there were no significant differences between the three groups on the temperature
that was used during the Pain task (oxytocin administration group: M = 46.2, SD = 1.1; condi-
tioned oxytocin group: M = 46.4, SD = 1.2; placebo group: M = 45.3, SD = 1.6; F (2, 73) =
0.537, p = 0.587).
Discussion
This is the first study that investigated the effects of pharmacological conditioning with oxyto-
cin on brain activity. We hypothesized that conditioned oxytocin responses would demon-
strate patterns of brain activation similar to exogenous oxytocin administration and that both
these groups would differ from the placebo group. Differences in the brain activation between
the oxytocin administration and placebo groups were demonstrated in the right amygdala and
in two clusters in superior temporal gyrus for the emotional faces task only, while brain activa-
tion of the conditioned oxytocin group was in between that of the oxytocin administration and
the placebo group but did not significantly differ from either group.
The amygdala has been shown to play a role in negative emotion processing [37] and its
activation has been found in response to threat [38]. Previous research has demonstrated that
presentation of faces with fearful expression increases amygdala activation and 24 IU oxytocin
has been repeatedly shown to dampen this effect [12, 13, 39]. We replicated these previous
findings and furthermore showed that there is a careful indication that conditioning with oxy-
tocin might slightly affect this activity pattern as well but to a lesser extent than exogenous
Table 3. Effects of the sound valence across the groups (second level analysis).
Placebo group (n = 29) Oxytocin group (n = 26) Conditioned group (n = 23)
Cluster
size
T
max
X
(mm)
Y
(mm)
Z
(mm)
Cluster
size
T
max
X
(mm)
Y
(mm)
Z
(mm)
Cluster
size
T
max
X
(mm)
Y
(mm)
Z
(mm)
Cry > control
WB right STG with extension
to right planum polare
2980 9.75 58 -10 -2 1185 7.3 64 -14 2 33 5.6 64 -24 4
WB left planum polare 2489 10.1 -54 -4 2 1034 6.99 -50 -10 4
ROI left amygdala 15 3.92 -22 -6 -14
ROI right amygdala 45 5.09 32 8 -20
ROI left insula 310 7.64 -50 -2 -2 94 6.26 -46 -8 0
ROI right insula 300 7.56 50 4 -4 69 6.15 50 -4 -4
ROI left IFG, pars triangularis 56 3.75 44 32 4
WB- results obtained with the whole brain analysis; ROI- results obtained with the region of interest analysis; STG- superior temporal gyrus; IFG = inferior frontal
gyrus. Reported activations are corrected for multiple comparisons with the threshold-free cluster enhancement. Coordinates are reported using the Montreal
Neurologic Institute space.
https://doi.org/10.1371/journal.pone.0229692.t003
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oxytocin. However, since no significant differences between the conditioned group and other
two groups were found, this finding should be interpreted cautiously.
Moreover, the same fearful > neutral contrast yielded a significant difference between the
oxytocin administration and placebo group in two clusters of the superior temporal gyrus
(STG). The STG plays an important role in the processing of emotional stimuli and social cog-
nition [40] and particularly processing of fearful faces [12, 41]. With this finding we thus repli-
cated previous results showing increased STG activity in response to the presentation of the
fearful faces. However, the direction of this oxytocin effect does not correspond to most previ-
ous studies. Several previous studies showed enhanced STG activity in response to emotional
Table 4. Effects of the pain stimulation across the groups (second level analysis).
Placebo group (n = 25) Oxytocin group (n = 23) Conditioned group (n = 25)
Cluster
size
T
max
X
(mm)
Y
(mm)
Z
(mm)
Cluster
size
T
max
X
(mm)
Y
(mm)
Z
(mm)
Cluster
size
T
max
X
(mm)
Y
(mm)
Z
(mm)
pain>control
WB right postcentral gyrus with
extension to precentral gyrus
10776 6.82 48 -26 64 455 6.36 48 -20 58 21 4.81 60 -4 28
WB left temporal occipital fusiform
cortex
1786 5.23 -28 -38 -24
WB left temporal occipital fusiform
cortex with extension to left
occipital fusiform gyrus
27763 8.18 -26 -46 -10
WB right parahippocampal gyrus
with extension to temporal
fusiform cortex
623 6.77 26 -24 -24 32709 7.79 22 -22 -18
WB bilateral occipital pole 248 5.19 0 -88 40
WB right lateral occipital cortex 217 4.89 44 -68 26
WB bilateral precuneous cortex 162 4.15 10 -60 14
WB left thalamus 118 4.8 -14 -32 10
WB left middle temporal gyrus 87 4.35 -68 -8 -10 25 4.01 -52 -12 -18
WB brain stem 81 4.68 -2 -26 -22
WB angular gyrus 33 3.45 48 -54 30
WB right cingulate gyrus 21 3.57 8 -50 6
WB bilateral cuneal cortex 15 3.26 -2 -84 36
WB frontal pole with extension to
right paracingulate gyrus
1212 5.54 0 66 4
WB left superior frontal gyrus 278 5.12 -24 22 42
ROI left amygdala 78 4.53 -20 -10 -24 18 5.03 -20 -16 -18
26 4.37 -26 -2 -32
ROI right amygdala 38 4.55 14 -4 -24 173 4.17 24 2 -26
pain < control
WB right precentral gyrus 837 6.52 46 10 26
WB left precentral gyrus 23 5.55 -58 6 4
WB right frontal operculum cortex
to insula and central opercular
cortex
1484 11 48 18 0
WB right central opercular cortex 121 5.79 52 0 8
WB right frontal pole 68 5.53 40 38 8
WB right insular cortex 422 6.95 34 12 10
WB- results obtained with the whole brain analysis; ROI- results obtained with the region of interest analysis. Reported activations are corrected for multiple
comparisons with the threshold-free cluster enhancement. Coordinates are reported using the Montreal Neurologic Institute space.
https://doi.org/10.1371/journal.pone.0229692.t004
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and social stimuli after oxytocin administration [26, 42]. However, in our study we found that
participants in the oxytocin group had lower activation in the STG on the contrast fear > neu-
tral in comparison to the placebo group. Some studies, also found dampening effects of oxyto-
cin on STG activation. For example, a decrease in STG activity after oxytocin administration
was found in response to social rejection [43]. Also, Hech and colleagues [44] demonstrated
that oxytocin reduced brain activation to social stimuli and, particularly, that individuals with
higher levels of social processing exhibited oxytocin induced decrease in STG in response to
social stimuli. The findings on the directionality of STG brain activity in response to oxytocin
are thus mixed in the current literature. In our study, we found an increase in STG in response
to fearful faces in the placebo condition and this increase was dampened by oxytocin in the
oxytocin condition, corresponding to our findings in the amygdala. Again, STG activity in the
conditioned oxytocin group was in between the oxytocin and placebo groups but did not sig-
nificantly differ from both groups. Possibly, similar to the results of the study on social rejec-
tion [43], oxytocin inhibited the processing of negative emotions of fearful faces in our study.
The significant differences were found between oxytocin administration and placebo
groups in these two areas, and at the same time the activation in the conditioned group was in
between these two groups and did not significantly differ from them. This finding might be
indicative of a smaller response of the conditioned group in comparison to the effect of oxyto-
cin administration, however this should be interpreted with caution. Possibly, there was not
enough power in the between-subject design of this study to find this small effect.
The sounds of a crying baby activated the auditory cortex in all groups and the amygdala
and the inferior frontal gyrus, pars triangularis in the placebo group, as was expected [29].
Even though significant activation by the cry> control contrast was found in the amygdala
and inferior frontal gyrus pars triangularis in the placebo group and not in the oxytocin
administration and conditioned oxytocin groups on the second level analyses, the between-
group comparison in the third level analysis did not reach significance. A previous study [31]
found that oxytocin reduced activation in the amygdala and increased activation in the insula
and the inferior frontal gyrus pars triangularis on the contrast cry> control. We could not
replicate these results. Speculatively, this could be due to design differences, as Riem and col-
leagues [31] included twins in their sample, and performed the task 45 minutes after the oxyto-
cin administration while our task was done approximately 60 minutes after the spray (as it
followed the faces task).
The pain task activated large clusters across the brain, including primary and secondary
somatosensory cortex, thalamus, cingulate gyrus and amygdala, the areas that have been
repeatedly shown to be activated by acute pain [45, 46]. Importantly, several studies showed
that oxytocin affects brain responses to experimentally induced pain and particularly dampens
amygdala activation [18, 20, 46]. Indeed, the increased activation on the contrast
pain> control in the left and right amygdala was found only in the placebo group and not in
the conditioned and oxytocin administration groups in the second level analyses, but the
between-group comparison was not significant. Possibly, the effects of both exogenous and
conditioned oxytocin were not strong enough to be seen in the between-group comparison.
The evidence about the effects of oxytocin on brain activation in response to pain, is, not con-
clusive. Singer and colleagues [18] found that oxytocin decreases amygdala activation in
response to heat pain stimuli, however, they proposed that the effects were driven by selfish
participants: effects of oxytocin on the amygdala activation were found only in selfish, but not
prosocial participants. Another study by Zunhammer and colleagues [19] did not find effects
of oxytocin on brain activity in response to heat pain. Speculatively, oxytocin might influence
emotional or social aspects of pain perception that have not been captured by our study as, for
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example, it has been shown that oxytocin enhances the pain-relieving effects of social support
[47] and affects neural activity while seeing pain in others [48].
The results of both the crying baby sounds and pain task showed that the second level analy-
ses are partially in line with the previous literature as heightened amygdala activation in response
to the crying sounds and pain stimulation was found in the placebo group but not in the oxyto-
cin administration group. However, the effects were not strong enough to be seen in the
between-group comparisons. One possible explanation for this lack of significance can be the
timing of the experiment. We conducted the MRI scanning on the third evocation day to avoid
interference with the conditioning procedure, because it has been previously shown that present-
ing a distinctive additional stimulus during the conditioning might inhibit the conditioned
response [49] and the whole MRI environment can be perceived to be stressful and distracting.
On the third evocation day, the conditioned response in saliva had already been extinguished
even though it was found on the first evocation day [24]. Since salivary oxytocin levels might not
be the only indicator of the conditioned response, we still hypothesized that we could observe
the conditioned response in the brain. Speculatively, if the fMRI experiment was done on the
first evocation day, a stronger response in the brain might have been found. Future studies are
needed to confirm this hypothesis. Moreover, the fMRI scan started approximately 50 minutes
after the oxytocin and placebo administration. This time frame was chosen because the neuronal
effects of exogenous oxytocin administration have been demonstrated to be the strongest around
this time [50]. However, the conditioned response does not necessarily correspond to the timing
of the effects of exogenous oxytocin administration. The only study on endocrine conditioning
that investigated the conditioned response temporally was a study on conditioned insulin release
[5] which found that the conditioned insulin release appeared around 40 minutes after the first
placebo administration. However, insulin and oxytocin are distinct systems and the results from
insulin conditioning cannot necessarily be directly generalized to the timing of oxytocin condi-
tioning. As the highest conditioned oxytocin levels in saliva were found immediately after the
conditioned stimulus administration on the first evocation day [24], the strongest response in
the brain might possibly also immediately follow the conditioned stimulus administration and
may already have decreased 50 minutes later. The fact that the only difference between the
groups was found on the first task and not on the subsequent tasks supports this speculation to
some extent. For future studies, it is advised that the effects of oxytocin conditioning are studied
on the first evocation day, and possibly immediately following the placebo administration with
repeated measurements across time to find the peak of the conditioned response.
Another possible explanation of the non-significant effects of conditioned oxytocin release
on brain activity, is the difference in the magnitude of the effects between exogenous oxytocin
administration and the conditioned response. Our data shows that even during evocation day
1, when the largest conditioned response was found in saliva, the oxytocin levels increased
twice from the baseline, compared to a 100-time increase in the oxytocin administration
group. It is unknown whether salivary oxytocin increase corresponds to the change in the
brain activity in a linear way, but it can be expected that the neural effects of conditioned oxy-
tocin release might be much smaller than the effects of oxytocin administration. However,
even small natural variations of the endogenous oxytocin levels have been shown to affect
brain activity, for example, in resting state [51], during massage [52], and in response to aver-
sive stimuli [53]. Therefore, it could be expected that endogenous oxytocin release triggered by
conditioning, would be strong enough to affect brain activity.
Changing hormonal levels with a behavioral manipulation can have important clinical
implications especially for disorders related to dysfunction of the endocrine system. For exam-
ple, it has been demonstrated that immunosuppressive treatment for renal transplant patients
can be enhanced by using classically conditioned immunosuppression [28]. Nevertheless,
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classically conditioned endocrine responses have not been investigated in clinical practice. The
possibility to induce classically conditioned insulin release as demonstrated by Stockhorst, de
Fries [5], might for example be applied for improving therapies for patients with diabetes type-
2 who suffer from dysfunctional insulin release. Classical conditioning of oxytocin responses
could be tested in populations with mental disorders related to emotional deficits, such as
autism, schizophrenia and borderline personality disorder as oxytocin has been shown to have
promising effects for treatments of these disorders [54, 55, 56]. Knowing what brain areas are
involved in endocrine conditioning might be helpful for making the effects of the endocrine
conditioning stronger and manipulating these effects more optimally.
To conclude, our study was the first study investigating the effects of classical conditioning
with oxytocin on brain activity. We have found preliminary indications that the conditioned
oxytocin response might affect the activity in the left STG and amygdala in a direction similar
to exogenous oxytocin, however future studies are needed to confirm this hypothesis as no sig-
nificant group difference between conditioned and other two groups was found in the current
study. Moreover, these effects were not generalizable across the tasks. Future research should
explore different time frames of the conditioned oxytocin brain responses and extend this par-
adigm to the conditioning of other hormones as comparisons to oxytocin conditioning.
Unraveling the neural mechanisms of endocrine conditioning might help us to implement this
potentially beneficial mechanism in clinical practice.
Supporting information
S1 Fig. Second level whole brain analysis in the placebo group in the faces task on the con-
trast neutral < fearful.
(TIF)
S2 Fig. Second level whole brain analysis in the oxytocin group in the faces task on the con-
trast neutral < fearful.
(TIF)
S3 Fig. Second level whole brain analysis in the conditioned group in the faces task on the
contrast neutral < fearful.
(TIF)
S4 Fig. Second level whole brain analysis in the conditioned group in the faces task on the
contrast and neutral < happy.
(TIF)
S5 Fig. Second level whole brain analysis in the placebo group in the crying sounds task on
the contrast control < cry.
(TIF)
S6 Fig. Second level whole brain analysis in the oxytocin group in the crying sounds task
on the contrast control < cry.
(TIF)
S7 Fig. Second level whole brain analysis in the conditioned group in the crying sounds
task on the contrast control < cry.
(TIF)
S8 Fig. Second level whole brain analysis in the placebo group in the pain task on the con-
trast control < pain.
(TIF)
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S9 Fig. Second level whole brain analysis in the placebo group in the pain task on the con-
trast control > pain.
(TIF)
S10 Fig. Second level whole brain analysis in the oxytocin group in the pain task on the
contrast control < pain.
(TIF)
S11 Fig. Second level whole brain analysis in the oxytocin group in the pain task on the
contrast and control > pain.
(TIF)
S12 Fig. Second level whole brain analysis in the conditioned group in the pain task on the
contrast control < pain.
(TIF)
S13 Fig. Second level whole brain analysis in the conditioned group in the pain task on the
contrast control > pain.
(TIF)
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